This is a specific type of lymphoma that starts in the skin. It's called 'anaplastic large cell' because the cancer cells look very abnormal and are large. It's 'primary' because it starts in the skin itself, not spreading from elsewhere. It's also called 'CD30-positive' because the cancer cells express a protein called CD30.
Every report comes from a Lived member, sent anonymously.
Have you tried Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma?
Primary cutaneous anaplastic large cell lymphoma is a rare cancer of T cells, a type of white blood cell, that starts in the skin and usually stays there. It most often appears as a single firm, red or purplish lump, or a small cluster of lumps, that can grow over weeks and sometimes breaks open into a sore. Lesions can appear anywhere, most commonly on the legs, head and neck, arms or trunk. About a quarter of people have lumps in more than one area of skin. The name describes what the cells look like under a microscope: large, unusual-looking cells that carry a marker called CD30 on their surface. It belongs to a family of skin conditions called CD30-positive lymphoproliferative disorders, which also includes lymphomatoid papulosis, a related condition whose small bumps come and go on their own. The most important thing to understand is that this skin-based lymphoma is different from systemic anaplastic large cell lymphoma, which starts in lymph nodes or organs and needs intensive chemotherapy. The skin form usually grows slowly, responds well to local treatment and has an excellent long-term outlook, so getting the distinction right protects people from treatment they do not need.
The cause is not known, and no lifestyle habit or exposure has been shown to bring it on. It is most often diagnosed in middle-aged and older adults, around age 60 on average, and is slightly more common in men. It is rare in children. A weakened immune system appears to raise the risk. Cases have been reported after organ transplants, in people taking immune-suppressing medicines such as TNF inhibitors (a group of drugs used for conditions like rheumatoid arthritis and Crohn's disease), and in people living with HIV. These are associations seen in a minority of cases; most people with this lymphoma have none of them.
Because the lumps can look like insect bites, cysts or other harmless skin growths, this lymphoma is often not recognized at first. Diagnosis requires a skin biopsy, usually a punch or excisional biopsy that removes a deep enough piece of tissue for testing. A pathologist examines the cells and uses special stains to confirm CD30 and other markers. Shallow shave biopsies often do not provide enough tissue. The biopsy alone cannot always separate this lymphoma from lymphomatoid papulosis, whose lesions clear on their own within about 3 to 12 weeks. Watching the lesion for several weeks can help: a lump that persists points toward lymphoma. The doctor will also review recent medicines, since some drug reactions can look similar under the microscope. Once the diagnosis is likely, staging tests check whether the lymphoma is truly limited to the skin. These usually include blood tests, an HIV test and a CT or PET-CT scan of the body. Any enlarged lymph node is biopsied. A small number of people have lymphoma in one nearby group of lymph nodes; this does not appear to worsen the outlook much, but lymphoma found in distant nodes or organs means a systemic lymphoma, which is treated differently.
Treatment is usually local and aims to clear the visible lesions with as little burden as possible. For a single lump or a small group of lumps, radiation therapy to that area is the standard first choice, sometimes after or instead of surgically removing the lesion. Radiation is usually well tolerated, causing mainly temporary redness or itching of the treated skin. It controls treated lesions very well, but it does not stop new ones from appearing elsewhere. When lesions are widespread, keep returning or involve nearby lymph nodes, medicines that work throughout the body are used. Brentuximab vedotin (Adcetris), an antibody that carries a cancer-killing drug directly to CD30-positive cells, is given by IV infusion every three weeks. In a randomized trial of people who had already been treated, about three in four with this lymphoma had a lasting response to brentuximab vedotin, compared with one in five on older options. Its main drawback is nerve damage that causes numbness or tingling in the hands and feet; this improves or resolves for most people after treatment stops. Low-dose methotrexate, a long-established medicine taken once a week, is another option and needs regular blood tests to watch the blood counts and liver. Other choices include bexarotene (a vitamin A-related medicine), creams or gels applied to the skin, and newer drugs under study. Multi-drug chemotherapy, once common, is not recommended for this lymphoma unless it has spread beyond the skin and nearby nodes. Because the condition is rare, most evidence comes from case series rather than large trials, and care is often shared between a dermatologist and a lymphoma specialist.
Most people do very well. In recent studies, roughly 86 to 95 percent of people had not died of this lymphoma five years after diagnosis, and many people live with it as a long-term, manageable skin condition. New or returning lumps are common, affecting about 40 to 50 percent of people at some point. A relapse in the skin usually does not mean the disease has become dangerous, and it can generally be treated again with radiation or another of the same options. People with many tumors on a single arm or leg may have a less predictable course. Follow-up involves regular skin checks and examination of lymph nodes, often for many years. A minority of people, estimated at roughly 10 to 15 percent, develop lymphoma outside the skin, sometimes years after the first diagnosis, which is why long-term follow-up continues even during remission.
Arrange a visit with a dermatologist for a skin lump or sore that keeps growing, breaks open, or has not cleared after several weeks, especially if it was dismissed as a bite or infection that never healed. If you have been diagnosed, contact your care team about new skin lumps, new or enlarging lymph nodes in the neck, armpit or groin, or numbness, tingling or weakness in the hands or feet during brentuximab vedotin treatment. Swollen nodes should be checked even if you have been in remission for years.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Primary Cutaneous Anaplastic Large Cell Lymphoma is like, what's helped you, or ask the community a question.